Eisai Europe Limited is a leading pharmaceutical company based in the United Kingdom, operating in the Specialty Pharma sector. The company is committed to improving the lives of patients through the development and commercialization of innovative medicines. Eisai Europe Limited is a subsidiary of Eisai Co., Ltd., a global pharmaceutical company headquartered in Japan. The company has a strong presence in Europe, with offices in the United Kingdom, Germany, France, Italy, Spain, and Switzerland.

Eisai Europe Limited is committed to sustainability and decarbonisation, and has set ambitious targets to reduce its carbon footprint. The company has implemented a range of initiatives to reduce its energy consumption and increase the use of renewable energy sources. These initiatives include the installation of solar panels on the roof of its UK headquarters, the use of energy-efficient lighting and heating systems, and the implementation of a corporate energy management system.

In addition, Eisai Europe Limited has signed a corporate power purchase agreement (PPA) with a renewable energy provider. This PPA allows the company to purchase renewable energy directly from a wind farm, which helps to reduce its carbon footprint and support the development of renewable energy infrastructure. The PPA also provides Eisai Europe Limited with a stable and predictable source of renewable energy, which helps to mitigate the risks associated with fluctuating energy prices.

Eisai Europe Limited is committed to reducing its carbon footprint and has set a target to achieve carbon neutrality by 2040. The company is working to achieve this target through a range of initiatives, including the implementation of energy-efficient technologies, the use of renewable energy sources, and the reduction of its overall energy consumption. The company is also exploring new ways to reduce its carbon footprint, such as the use of electric vehicles and the implementation of green building standards.

Eisai Europe Limited is committed to sustainability and is taking a proactive approach to decarbonisation. The company recognizes that reducing its carbon footprint is not only good for the environment, but also makes good business sense. By reducing its energy consumption and increasing the use of renewable energy sources, Eisai Europe Limited is able to reduce its operating costs and improve its bottom line. The company is also able to enhance its reputation as a responsible and sustainable business, which can help to attract and retain customers, employees, and investors.

In conclusion, Eisai Europe Limited is a leading pharmaceutical company operating in the Specialty Pharma sector. The company is committed to sustainability and decarbonisation, and has set ambitious targets to reduce its carbon footprint. Eisai Europe Limited has implemented a range of initiatives to reduce its energy consumption and increase the use of renewable energy sources, including the installation of solar panels, the use of energy-efficient lighting and heating systems, and the implementation of a corporate energy management system. The company has also signed a corporate PPA with a renewable energy provider, which allows it to purchase renewable energy directly from a wind farm. Eisai Europe Limited is committed to achieving carbon neutrality by 2040 and is taking a proactive approach to decarbonisation. The company recognizes that reducing its carbon footprint is not only good for the environment, but also makes good business sense, and is committed to enhancing its reputation as a responsible and sustainable business.